Overview

Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out". This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Peregrine Pharmaceuticals